Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sona Nanotech Inc C.SONA

Alternate Symbol(s):  SNANF

Technology Scientific & Technical Instruments
Sona Nanotech Inc. is a nanotechnology life sciences company, which is engaged in developing targeted hyperthermia therapy. The Company has developed multiple methods for the manufacturing of various types of gold nanoparticles (GNR). It is engaged in research and development of its technology for use in multiplex diagnostic testing platforms and advanced biomedical applications. Its gold nanotechnologies are adapted for use in applications, as a safe and delivery system for multiple medical treatments, for the approval of various regulatory boards, including Health Canada and the Food and Drug administration (FDA). Its gold nanorod particles are manufactured without the use of cetyltrimethylammonium bromide (CTAB), eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. The Company is focused on the development of a pre-clinical nanomedical therapy for the treatment of cancer using its biocompatible GNR.


CSE:SONA - Post by User

Sona Nanotech Inc
Bullboard Posts
User Avatar Image
(1191)
•••
Comment by Moemoney42on Jul 04, 2020 8:18pm
107 Views
Post# 31225028

RE:RE:RE:96.6% accurate point of contact

RE:RE:RE:96.6% accurate point of contact
dart321 wrote: then again they could come out with a sales news release Monday. Then my numbers would have to be adjusted up to include the additional sales. Which would in turn add stronger speculation. I guess the only thing we know for certain is it will move up.

Although sales are a nice barometer of success.. it boils down to profit.. if there's tests out there being sold for less, SONA's test may not capture the amount of the market some here think it will... if the margins get squeezed it could get challanging.. pie in the sky predictions of $1000/share are just foolish dreaming...LOL.. But I guess it doesn't cost nothing to dream.. just don't loose the bird in the hand for the proverbial two in the bush.. ;-)
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities